Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 24 04:00PM ET
12.62
Dollar change
-0.52
Percentage change
-3.96
%
Index- P/E- EPS (ttm)-0.69 Insider Own54.73% Shs Outstand12.85M Perf Week-3.30%
Market Cap162.55M Forward P/E- EPS next Y- Insider Trans1.13% Shs Float5.83M Perf Month-35.12%
Income-8.89M PEG- EPS next Q-0.20 Inst Own4.84% Short Float2.41% Perf Quarter46.92%
Sales0.00M P/S- EPS this Y-11.76% Inst Trans-23.11% Short Ratio2.71 Perf Half Y62.42%
Book/sh0.52 P/B24.20 EPS next Y- ROA-86.87% Short Interest0.14M Perf Year12.58%
Cash/sh0.54 P/C23.25 EPS next 5Y- ROE-89.30% 52W Range7.58 - 21.44 Perf YTD19.96%
Dividend Est.- P/FCF- EPS past 5Y-36.91% ROI-132.71% 52W High-41.14% Beta3.34
Dividend TTM- Quick Ratio23.74 Sales past 5Y0.00% Gross Margin- 52W Low66.49% ATR (14)1.37
Dividend Ex-Date- Current Ratio23.74 EPS Y/Y TTM-13.46% Oper. Margin0.00% RSI (14)35.68 Volatility10.43% 8.79%
Employees7 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price36.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q3.13% Payout- Rel Volume0.55 Prev Close13.14
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume51.80K Price12.62
SMA20-21.85% SMA50-16.74% SMA20014.66% Trades Volume28,651 Change-3.96%
Date Action Analyst Rating Change Price Target Change
Sep-01-21Initiated H.C. Wainwright Buy $78
Apr-15-24 10:53PM
Apr-10-24 03:30PM
Mar-13-24 06:00AM
Mar-12-24 06:00AM
Mar-07-24 09:00AM
06:00AM Loading…
Feb-27-24 06:00AM
Feb-22-24 06:00AM
Feb-14-24 06:00AM
Nov-21-23 06:00AM
Sep-13-23 05:02PM
Jul-26-23 01:12PM
Jul-18-23 06:53AM
May-10-23 06:32AM
May-09-23 06:40AM
May-08-23 06:41AM
06:58AM Loading…
May-05-23 06:58AM
May-04-23 06:29AM
May-03-23 06:46AM
May-02-23 06:46AM
May-01-23 06:45AM
Apr-28-23 07:04AM
Apr-27-23 06:47AM
Apr-26-23 06:26AM
Apr-20-23 07:03AM
Apr-19-23 06:53AM
Apr-17-23 06:54AM
Apr-14-23 06:37AM
Apr-13-23 06:52AM
Apr-12-23 07:07AM
Apr-11-23 06:58AM
06:44AM Loading…
Apr-10-23 06:44AM
Apr-07-23 07:44AM
Apr-06-23 10:37AM
07:20AM
Apr-05-23 06:11AM
Apr-04-23 07:08AM
Apr-03-23 06:48AM
Mar-31-23 06:36AM
Mar-30-23 06:36AM
Mar-29-23 06:32AM
Mar-28-23 06:46AM
Mar-24-23 06:42AM
Mar-23-23 07:01AM
Mar-21-23 06:23AM
Mar-20-23 06:35AM
Mar-17-23 06:47AM
Mar-16-23 06:51AM
Mar-15-23 06:44AM
Mar-13-23 06:32AM
Mar-10-23 07:04AM
Mar-09-23 06:33AM
Mar-08-23 06:30AM
Mar-07-23 06:34AM
Mar-06-23 07:22AM
Mar-03-23 06:38AM
Mar-02-23 06:44AM
Mar-01-23 06:01AM
Feb-28-23 06:43AM
Feb-27-23 06:50AM
Feb-24-23 07:17AM
Feb-23-23 07:21AM
Feb-22-23 06:56AM
Feb-21-23 07:35AM
Feb-17-23 06:27AM
Feb-16-23 07:28AM
Feb-15-23 07:01AM
Feb-14-23 06:23AM
Feb-13-23 07:30AM
Feb-10-23 06:42AM
Feb-09-23 06:51AM
Feb-08-23 06:45AM
Feb-07-23 06:46AM
Feb-06-23 06:56AM
Feb-03-23 06:32AM
Feb-02-23 06:43AM
Feb-01-23 06:14AM
05:30AM
Jan-31-23 06:50AM
Jan-30-23 06:42AM
Jan-27-23 07:00AM
Jan-26-23 06:44AM
Jan-25-23 06:39AM
06:39AM
Jan-11-23 06:53AM
Jan-05-23 05:10AM
Jan-04-23 06:54AM
Dec-29-22 06:51AM
06:48AM
Dec-28-22 06:58AM
Dec-27-22 07:11AM
Dec-23-22 06:32AM
Dec-22-22 06:34AM
Dec-21-22 09:55AM
06:46AM
Dec-01-22 06:00AM
Oct-28-22 06:53AM
Oct-11-22 11:54AM
Sep-30-22 09:22AM
Aug-18-22 07:59AM
Aug-11-22 10:30AM
Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Patel SnehalCEO and CFOApr 01 '24Buy19.083,00057,2405,350,777Apr 03 06:10 AM
Patel SnehalCEO and CFOMar 22 '24Buy19.982,50049,9505,347,777Mar 26 06:05 AM
Patel SnehalCEO and CFOMar 20 '24Buy17.681,50026,5205,345,277Mar 22 06:02 AM
Patel SnehalCEO and CFOMar 05 '24Buy12.4930,500380,9455,343,777Mar 07 06:05 AM
Patel SnehalCEO and CFOMar 04 '24Buy13.034,10053,4235,340,277Mar 06 06:05 AM
Patel SnehalCEO and CFOFeb 16 '24Buy11.1610,800120,5285,336,177Feb 21 06:05 AM
Patel SnehalCEO and CFOFeb 15 '24Buy11.0712,700140,5895,325,377Feb 20 06:04 AM
Patel SnehalCEO and CFONov 10 '23Buy10.175,00050,8385,312,677Nov 14 06:05 AM
Patel SnehalCEO and CFONov 03 '23Buy9.113,50031,8855,307,677Nov 07 06:15 AM
Thompson JayeVP Clinical Reg AffairsOct 27 '23Buy8.575004,285260,348Oct 31 06:16 AM
Patel SnehalCEO and CFOOct 26 '23Buy7.972,50019,9255,304,177Oct 30 06:15 AM
Patel SnehalCEO and CFOOct 25 '23Buy7.912,50019,7755,301,677Oct 27 06:15 AM
Patel SnehalCEO and CFOOct 10 '23Buy9.071,0009,0705,299,177Oct 12 06:05 AM
Patel SnehalCEO and CFOOct 04 '23Buy8.632,00017,2605,298,177Oct 05 06:05 AM
Thompson JayeVP Clinical Reg AffairsSep 26 '23Buy8.716005,226259,848Sep 28 06:05 AM
Patel SnehalCEO and CFOSep 19 '23Buy8.954,00035,8005,296,177Sep 21 06:05 AM
Patel SnehalCEO and CFOSep 11 '23Buy9.481,0009,4805,292,177Sep 13 06:05 AM
Patel SnehalCEO and CFOAug 22 '23Buy9.971,0009,9705,291,177Aug 24 06:05 AM
Patel SnehalCEO and CFOAug 04 '23Buy10.552,00021,1005,290,177Aug 08 06:05 AM
Patel SnehalCEO and CFOJul 21 '23Buy9.201,0009,2005,288,177Jul 25 06:15 AM
Thompson JayeVP Clinical Reg AffairsJul 13 '23Buy9.492502,372259,248Jul 17 06:15 AM
Patel SnehalCEO and CFOMay 17 '23Buy11.691,00011,6905,287,177May 18 06:01 AM
Thompson JayeVP Clinical Reg AffairsApr 28 '23Buy11.222502,805258,998May 02 06:06 AM